Total androgen blockade for metastatic cancer of the prostate.
This randomized, double-blind study comparing orchiectomy plus placebo to orchiectomy plus a nonsteroid antiandrogen (Anandron) shows that total androgen blockade for metastatic cancer of the prostate provides a significantly better early objective response when compared to castration alone. This response, however, is less apparent at 18 months. The study also suggests a longer survival for the patients with total androgen blockade.
Béland
G
G
Service of Urology, Notre-Dame Hospital, University of Montreal, Québec, Canada.
Elhilali
M
M
Fradet
Y
Y
Laroche
B
B
Ramsey
E W
EW
Trachtenberg
J
J
Venner
P M
PM
D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002064:Buserelin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D048289:Imidazolidines; D008297:Male; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000601:surgery; D009919:Orchiectomy; D010919:Placebos; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery*; D011897:Random Allocation; D012074:Remission Induction
D000726:Androgen Antagonists; D007093:Imidazoles; D048289:Imidazolidines; D010919:Placebos; C021277:nilutamide; D002064:Buserelin